TuHURA Biosciences announced its Q3 2026 financial results and highlighted progress in its cancer immunotherapy programs, including promising early data for IFx-2.0 combined with Keytruda in metastatic Merkel cell carcinoma and FDA clearance to start a Phase 1b trial for TBS-2025 in acute myeloid leukemia. The company also secured patents for its VISTA inhibitor and Delta Opioid Receptor technologies and maintains strong funding through a $50 million credit facility. Upcoming milestones include further clinical trial results and presentations at the American Society of Hematology meeting in December 2026.
TuHURA Biosciences Q3 2026 results and updates provide context for readers. For those following health-sector stocks, 99 of 150 rose and 43 fell on Pluang. Notable movers as of Nov 13, 2026 19:41 WIB include MRVI at USD 7.83 (+1.95%), ACAD at USD 18.48 (+1.87%, mostly sell orders), and COGT at USD 28.62 (-1.78%, mostly buy orders).
Michelin has announced the total number of its voting rights and shares as of October 31, 2026. The company has 691,516,292 shares and 960,075,649 voting rights, considering 20,287,710 treasury shares. This disclosure complies with French regulations...
Michelin has disclosed the total number of voting rights and shares composing its capital as of October 31, 2026. The company reported 691,516,292 shares, with theoretical voting rights totaling 980,363,359 and exercisable voting rights at 960,075,64...
KeyBanc lowered its price target for YETI Holdings to $49, suggesting a 27.94% upside from the current $38.30 stock price. This follows YETI's reduction of its full-year adjusted sales growth forecast to about 6% from the previous 7-8%, citing consum...
Bernstein SocGen Group has reduced its price target for Applied Materials to $600, even though the company reported higher sales and profits in Q4 2026 driven by strong demand for semiconductor services, especially AI chips. Applied Materials posted ...
Boralex Inc. announced a private placement of $600 million Canadian dollars in green bonds, split into two series maturing in 2031 and 2036 with interest rates of 4.503% and 5.173%, respectively. This marks Boralex's first issuance of green corporate...
